In breast cancer patients with metastatic disease, bone is the most common site of metastasis and the most common site of first distant relapse, with roughly half (48%) of breast cancer patients ...

Two studies led by Baylor College of Medicine shed new light on the unanswered question of why estrogen receptor-positive (ER+) breast cancer sometimes grows back in the bone and spreads to other ...

Researchers from Tampere University, Finland, and Izmir Institute of Technology, Turkey, have developed an in vitro cancer model to investigate why breast cancer spreads to bone. Their findings hold ...

Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often undetectable and able to escape typical treatments. Unfortunately, these ...

American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer Bone is the most common site to ...

The aromatase inhibitors have been widely incorporated into the adjuvant breast cancer care of postmenopausal women with estrogen and/or progesterone receptor–positive breast cancer. Aromatase ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

In addition to their ability to protect and restore bone health for patients with early breast cancer, antiresorptive drugs have also been investigated for their oncologic benefits as adjuvant therapy ...

Bone density provides information that may help more accurately determine the risk of developing breast cancer. Measuring a woman’s bone mineral density can provide additional information that may ...

A drug of a class commonly used to combat bone loss may reduce by a third the chance that some breast cancers will spread or recur, a large study has found. While it may sound odd to treat cancer with ...